PERELMAN's $4.12 BIL. OFFER FOR GILLETTE IS 2-1/4 TIMES THE PRICE
PERELMAN's $4.12 BIL. OFFER FOR GILLETTE IS 2-1/4 TIMES THE PRICE that the financier paid to get into the cosmetics/toiletries business last year, but it is not enough to impress the financial market as a final bid. Gillette's stock quickly pushed above Perelman's offer of $65 cash per share and closed on Nov. 14 at $68. Revlon Chairman Ronald Perelman bought into the cosmetics/toiletries business with the hostile takeover of Revlon last autumn for $1.8 bil. Perelman eventually lowered his outlay for that deal to under $500 mil. via divestitures. Perelman's offer is valued at roughly 22 times Gillette's estimated full-year earnings. For Revlon, the original price was about six times after-tax earnings. The scope of the Revlon consolidation effort is highlighted by the fact that the company is simultaneously involved in an effort to buy the Max Factor/Halston/Almay group from International Playtex. That deal is waiting the completion of a leveraged buyout of Playtex from Beatrice. Perelman's acquisition activites have not raised antitrust issues to date. The vehicle for the Perelman/Revlon takeover is a company called Orange Acquisition Corporation, a wholly-owned subsidiary of a partnership formed by the Revlon Group and MacAndrews & Forbes (headed by Perelman). After purchasing an initial position in Gillette of 9.2 mil. shares (or 13.9% of the 63.4 mil. outstanding), Orange began a tender offer on Nov. 14; the initial deadline is Dec. 12. Drexel, Burnham Lambert is representing Perelman again. Gillette is using Morgan Stanley. Gillette's first response to the unsolicited takeover offer was to urge shareholder restraint in tendering.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth